Written Descriptions: How Much is Enough? Court Will Revisit Ariad Case to Clarify the Amount of Disclosure Necessary in Patents
01 February 2010
Foley Partner Courtenay Brinckerhoff authored an article titled, “Written Descriptions: How Much is Enough? Court Will Revisit Ariad Case to Clarify the Amount of Disclosure Necessary in Patents” in the Genetic Engineering & Biotechnology News. Brinckerhoff discusses the Federal Circuit’s decision to rehear Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. en banc to resolve an intra-court split over whether 35 USC § 112 imposes a written-description requirement that is separate from the enablement requirement. She reviews how the outcome of the case could have significant impact on biotechnology patents, which are often vulnerable to written-description challenges.
Author(s)
Related Insights
17 May 2025
Events
American Psychiatric Association – Telemedicine Prescribing of Controlled Substances: Your Legal & Regulatory Questions Answered
Nathaniel Lacktman, partner and chair of Foley’s Telemedicine & Digital Health Industry Team and chair-elect of the ATA Board of Directors, will be a speaker at the American Psychiatric Association Annual Meeting on May 20, 2025.
02 April 2025
Events
Investigating the Investigation: Navigating Regulatory Uncertainty in the Wake of a Breach
Following a cybersecurity incident, regulators are increasingly scrutinizing the breach response. This is especially true in the case of a mega breach.
19 February 2025
Foley Viewpoints
FinCEN Resumes Corporate Transparency Act Enforcement
The last remaining nationwide injunction prohibiting enforcement of the Corporate Transparency Act (CTA) has been stayed, clearing the way for the federal government to resume enforcing the CTA.